YOUYANG HU^1,#, YISHU LUO^1,#, TIANYUE XIE¹, YUEHUA CHEN^1,2, JUN ZHAO¹, WEICHAO JI³, ZHIWEI YAN³, SITONG QIU³, KEXIN GAO³, HAIXIA ZHU⁴, LIMIN MA^1,*, QIYOU YIN^1,*

Oncology Research, Vol.33, No.7, pp. 1695-1708, 2025, DOI:10.32604/or.2025.060021 - 26 June 2025

Abstract Objective: Neuroblastoma (NB) is frequently associated with high-risk pediatric cases that demonstrate limited response to cisplatin, contributing to a poor prognosis. Recent studies have explored the role of tumor cell senescence in increasing sensitivity to this chemotherapy agent. This study aims to identify genes related to cell senescence in children diagnosed with NB, evaluate their influence on cisplatin sensitivity, and investigate potential strategies to enhance the efficacy of chemotherapy. Methods: Gene expression profiles and clinical data were obtained for 498 NB patients from the GEO database (GSE49710). The study focused on identifying genes that were… More >

Chunmou Li^*1, Xiaomin Peng^*1, Chuchu Feng^*1, Xilin Xiong^*, Jianxin Li^†, Ning Liao^‡, Zhen Yang^§, Aiguo Liu^¶, Pingping Wu^*, Xuehong Liang^†, Yunyan He^‡, Xin Tian^§, Yunbi Lin^§, Songmi Wang^¶, Yang Li^*

Oncology Research, Vol.28, No.7-8, pp. 791-800, 2020, DOI:10.3727/096504021X16184815905096

Abstract This nonrandomized, multicenter cohort, open-label clinical trial evaluated the efficacy and safety of combined chemotherapy with arsenic trioxide (ATO) in children with stage 4/M neuroblastoma (NB). We enrolled patients who were newly diagnosed with NB and assessed as stage 4/M and received either traditional chemotherapy or ATO combined with chemotherapy according to their own wishes. Twenty-two patients were enrolled in the trial group (ATO combined with chemotherapy), and 13 patients were enrolled in the control group (traditional chemotherapy). Objective response rate (ORR) at 4 weeks after completing induction chemotherapy was defined as the main outcome,… More >

Shu Chen^*, Lianhua Jin^†, Shu Nie^†, Lizhi Han^†, Na Lu^†, Yan Zhou^†

Oncology Research, Vol.26, No.3, pp. 445-455, 2018, DOI:10.3727/096504017X14974834436195

Abstract Accumulating evidence indicates that microRNA-205 (miR-205) is involved in tumor initiation, development, and metastasis in various cancers. However, its functions in neuroblastoma (NB) remain largely unclear. Here we found that miR-205 was significantly downregulated in human NB tissue samples and cell lines. miR-205 expression was lower in poorly differentiated NB tissues and those of advanced International Neuroblastoma Staging System stage. In addition, restoration of miR-205 in NB cells suppressed proliferation, migration, and invasion and induced cell apoptosis in vitro, as well as impaired tumor growth in vivo. cAMP-responsive elementbinding protein 1 (CREB1) was identified as a More >